Opiant Pharmaceuticals, Inc., CEO Roger Crystal, M.D., to Present to President's Commission on Combating Drug Addiction and the Opioid Crisis

SANTA MONICA, Calif., Sept. 25, 2017 -- Opiant Pharmaceuticals, Inc., (“Opiant”) (NASDAQ:OPNT), today announced that Chief Executive Officer Roger Crystal, M.D., has been invited to testify before the President's Commission on Combating Drug Addiction and the Opioid Crisis and The Office of National Drug Control Policy leadership. Dr. Crystal will present to the commission, industry peers and meeting attendees regarding his experience and perspective on Innovative Pain Management and Prevention Measures for Diversion.

“I am honored to have been asked to represent Opiant and outline the work we’re doing to address addiction in America,” shared Roger Crystal, M.D., Chief Executive Officer of Opiant. “This meeting represents an opportunity for industry experts and advocates to come together to solve the drug epidemic we face and to outline effective strategies to prevent similar, addiction-based public health crises from debilitating future generations.”

The meeting will be held on Wednesday, September 27, 2017, 12:30 – 2:30 PM EDT at the Eisenhower Executive Office Building. The meeting will be livestreamed from the WhiteHouse.gov website, and details of the meeting can be accessed on the Federal Register’s Website.

Opiant collaborated with the National Institute on Drug Abuse (NIDA) to develop NARCAN® Nasal Spray, the only FDA-approved nasal naloxone, which is licensed to Adapt Pharma. Opiant remains committed to further innovation and product development in the addiction space. The company’s pipeline of nasal opioid antagonists addresses both Alcohol Use and Eating Disorders. Opiant is also developing additional therapies for Opioid Use Disorder, including advancing the pre-clinical development of its heroin vaccine candidate, which was licensed in October 2016 from the Walter Reed Army Institute of Research and NIDA. Opiant continues to maintain an active presence in national organizations such as the National Institutes of Health (NIH), where Dr. Crystal was recently invited to advise on the development of medications for Opioid Use Disorder.

About Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Operations Limited. For more information please visit: www.opiant.com. 

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

CONTACT INFORMATION:

Corporate Contact:
[email protected]

Media Contact:
Casey Myburgh
Ketchum Public Relations
[email protected]
202-835-8876

Investors:
Sam Martin
Argot Partners
[email protected]
212-600-1902